Condition: Breast Cancer · Breast Neoplasm · Breast Cancer Stage IV · Sponsor: MBQ Pharma
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
This description comes directly from the study's public registry record.
Scott Houston · (415) 404 8838 · scott.houston@mbqpharma.com
Jose Rodriguez-Orengo, PhD · jose.rodriguez@mbqpharma.com
Always discuss trial participation with your own doctor first.
| Precision Next Gen Oncology & Research Center | Beverly Hills, California, United States | Recruiting |
| Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI | Sarasota, Florida, United States | Recruiting |
| Sarah Cannon Research Institute/SCRI | Nashville, Tennessee, United States | Recruiting |
| FDI Clinical Research | San Juan, Puerto Rico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06075810